RETRACTED: PEGylation enhances tumor targeting of plasmid DNA by an artificial cationized protein with repeated RGD sequences, Pronectin® (Retracted article. See vol. 232, pg. 270, 2016)

被引:34
作者
Hosseinkhani, H [1 ]
Tabata, Y [1 ]
机构
[1] Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Field Tissue Engn,Sakyo Ku, Kyoto 6068507, Japan
关键词
tumor targeting; enhanced gene expression; pronectin; cationization; PEGylation;
D O I
10.1016/j.jconrel.2004.02.025
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The objective of this study is to investigate feasibility of a non-viral gene carrier with repeated RGD sequences (Pronectin F+) in tumor targeting for gene expression. The Pronectin F+ was cationized by introducing spermine (Sm) to the hydroxyl groups to allow to polyionically complex with plasmid DNA. The cationized Pronectin F+ prepared was additionally modified with poly(ethylene glycol) (PEG) molecules which have active ester and methoxy groups at the terminal, to form various PEG-introduced cationized Pronectin F+. The cationized Pronectin F+ with or without PEGylation at different extents was mixed with a plasmid DNA of LacZ to form respective cationized Pronectin F+-plasmid DNA complexes. The plasmid DNA was electrophoretically complexed with cationized Pronectin F+ and PEG-introduced cationized Pronectin F+, irrespective of the PEGylation extent, although the higher N/P ratio of complexes was needed for complexation with the latter Pronectin F+. The molecular size and zeta potential measurements revealed that the plasmid DNA was reduced in size to about 250 nm and the charge was changed to be positive by the complexation with cationized Pronectin F+. For the complexation with PEG-introduced cationized Pronectin F+, the charge of complex became neutral being almost 0 mV with the increasing PEGylation extents, while the molecular size was similar to that of cationized Pronectin F+. When cationized Pronectin F+-plasmid DNA complexes with or without PEGylation were intravenously injected to mice carrying a subcutaneous Meth-AR-1 fibrosarcoma mass, the PEG-introduced cationized Pronectin F+-plasmid DNA complex specifically enhanced the level of gene expression in the tumor, to a significantly high extent compared with the cationized Pronectin F+-plasmid DNA complexes and free plasmid DNA. The enhanced level of gene expression depended on the percentage of PEG introduced, the N/P ratio, and the plasmid DNA dose. A fluorescent microscopic study revealed that the localization of plasmid DNA in the tumor tissue was observed only for the PEG-introduced cationized Pronectin F+-plasmid DNA complex injected. We conclude that the PEGylation of cationized Pronectin F+ is a promising way to enable the plasmid DNA to target to the tumor for gene expression. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:157 / 171
页数:15
相关论文
共 81 条
[1]  
[Anonymous], BREAST CANC RES
[2]  
Aplin AE, 1998, PHARMACOL REV, V50, P197
[3]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[4]  
ATSUMI R, 1987, CANCER RES, V47, P5546
[5]   GENE-TRANSFER WITH SYNTHETIC CATIONIC AMPHIPHILES - PROSPECTS FOR GENE-THERAPY [J].
BEHR, JP .
BIOCONJUGATE CHEMISTRY, 1994, 5 (05) :382-389
[6]  
Boulikas T, 1996, INT J ONCOL, V9, P941
[7]   REQUIREMENT OF VASCULAR INTEGRIN ALPHA(V)BETA(3) FOR ANGIOGENESIS [J].
BROOKS, PC ;
CLARK, RAF ;
CHERESH, DA .
SCIENCE, 1994, 264 (5158) :569-571
[8]   INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS [J].
BROOKS, PC ;
MONTGOMERY, AMP ;
ROSENFELD, M ;
REISFELD, RA ;
HU, TH ;
KLIER, G ;
CHERESH, DA .
CELL, 1994, 79 (07) :1157-1164
[9]  
Budker V, 2000, J GENE MED, V2, P76, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<76::AID-JGM97>3.0.CO
[10]  
2-4